{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Farxiga&page=2",
    "query": {
      "intervention": "Farxiga",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Farxiga&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T19:46:54.237Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02338193",
      "title": "Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Prevention in Women After GDM Who Are at High-risk"
      ],
      "interventions": [
        {
          "name": "DAPA/MET XR",
          "type": "DRUG"
        },
        {
          "name": "DAPA",
          "type": "DRUG"
        },
        {
          "name": "MET XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Woman's",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 69,
      "start_date": "2015-09-22",
      "completion_date": "2019-03-13",
      "has_results": true,
      "last_update_posted_date": "2019-06-11",
      "last_synced_at": "2026-09-25T19:46:54.237Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02338193"
    },
    {
      "nct_id": "NCT00643851",
      "title": "An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "18 Years to 77 Years"
      },
      "enrollment_count": 994,
      "start_date": "2008-06",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2023-01-30",
      "last_synced_at": "2026-09-25T19:46:54.237Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Haleyville, Alabama • Tempe, Arizona + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Haleyville",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00643851"
    },
    {
      "nct_id": "NCT03168295",
      "title": "PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin 10mg then Placebo Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet then Dapagliflozin 10mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 34,
      "start_date": "2016-10",
      "completion_date": "2019-05-15",
      "has_results": true,
      "last_update_posted_date": "2020-09-17",
      "last_synced_at": "2026-09-25T19:46:54.237Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03168295"
    },
    {
      "nct_id": "NCT04697485",
      "title": "Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HF - Heart Failure",
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-01-08",
      "completion_date": "2022-03-30",
      "has_results": false,
      "last_update_posted_date": "2022-05-10",
      "last_synced_at": "2026-09-25T19:46:54.237Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04697485"
    },
    {
      "nct_id": "NCT02695173",
      "title": "Complications of UTI in Patients on Dapagliflozin",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Severe Complications of Urinary Tract Infections"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 683380,
      "start_date": "2017-01-01",
      "completion_date": "2020-11-30",
      "has_results": false,
      "last_update_posted_date": "2021-12-07",
      "last_synced_at": "2026-09-25T19:46:54.237Z",
      "location_count": 2,
      "location_summary": "Wilmington, Delaware • Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02695173"
    },
    {
      "nct_id": "NCT01662999",
      "title": "Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 42,
      "start_date": "2012-08",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2015-05-08",
      "last_synced_at": "2026-09-25T19:46:54.237Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01662999"
    },
    {
      "nct_id": "NCT07662044",
      "title": "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Elecoglipron",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Elecoglipron-matched placebo",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin-matched placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2026-07-06",
      "completion_date": "2028-07-14",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-09-25T19:46:54.237Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Daphne, Alabama • Lomita, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07662044"
    },
    {
      "nct_id": "NCT00726505",
      "title": "Renal Mechanism of Action/Splay vs. TmG",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes, NOS"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2009-06",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2016-10-17",
      "last_synced_at": "2026-09-25T19:46:54.237Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00726505"
    },
    {
      "nct_id": "NCT05932901",
      "title": "OPTIMISE-CKD Drug Utilization",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 2682052,
      "start_date": "2022-05-04",
      "completion_date": "2023-09-28",
      "has_results": false,
      "last_update_posted_date": "2024-04-17",
      "last_synced_at": "2026-09-25T19:46:54.237Z",
      "location_count": 1,
      "location_summary": "Minneota, Minnesota",
      "locations": [
        {
          "city": "Minneota",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05932901"
    },
    {
      "nct_id": "NCT02597049",
      "title": "A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Dulaglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 424,
      "start_date": "2015-11",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2020-06-17",
      "last_synced_at": "2026-09-25T19:46:54.237Z",
      "location_count": 13,
      "location_summary": "Encino, California • Huntington Park, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02597049"
    }
  ]
}